Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study

[1]  J. Blay,et al.  Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. , 2016, The Lancet. Oncology.

[2]  P. Rossen,et al.  Pazopanib in metastatic osteosarcoma: Significant clinical response in three consecutive patients , 2014, Acta oncologica.

[3]  Yanfeng Zhuang,et al.  Impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: a meta-analysis , 2014, Tumor Biology.

[4]  Jiong Hu,et al.  Clinical predictive value of serum angiogenic factor in patients with osteosarcoma. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[5]  M. Sharma,et al.  Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study , 2012, International Orthopaedics.

[6]  H. Rosenthal,et al.  Expression of Vascular Endothelial Growth Factor correlates with the advance of clinical osteosarcoma , 2012, International Orthopaedics.

[7]  P. Casali,et al.  A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  N. Theera-Umpon,et al.  Relationships between serum biomarker levels and clinical presentation of human osteosarcomas. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[9]  R. Morgan,et al.  Antiangiogenic effects of zoledronate on cancer neovasculature. , 2011, Future oncology.

[10]  Jianda Xu,et al.  Difference in Pre- and Postchemotherapy Vascular Endothelial Growth Factor Levels as a Prognostic Indicator in Osteosarcoma , 2011, The Journal of international medical research.

[11]  K. Szamotulska,et al.  A prognostic evaluation of vascular endothelial growth factor in children and young adults with osteosarcoma , 2011, Pediatric blood & cancer.

[12]  Xiao-Li Liu,et al.  Expression of b‐FGF and endostatin and their clinical significance in human osteosarcoma , 2010, Orthopaedic surgery.

[13]  P. Terrier,et al.  Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trial. , 2010, Current oncology.

[14]  G. Schinzari,et al.  Neoadjuvant multidrug chemotherapy including High-Dose Methotrexate modifies VEGF expression in Osteosarcoma: an immunohistochemical analysis , 2010, BMC musculoskeletal disorders.

[15]  G. Machak,et al.  Endostatin, Placental Growth Factor, and Fibroblast Growth Factors-1 and -2 in the Sera of Patients with Primary Osteosarcomas , 2009, Bulletin of Experimental Biology and Medicine.

[16]  V. Sreenivas,et al.  VEGF expression as a prognostic marker in osteosarcoma , 2009, Pediatric blood & cancer.

[17]  T. Yamashita,et al.  The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma. , 2009, The Journal of bone and joint surgery. British volume.

[18]  F. B. Sørensen,et al.  Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation , 2009, Sarcoma.

[19]  T. Yamashita,et al.  Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin , 2007, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.

[20]  D. Vanel,et al.  SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. , 2007, European journal of cancer.

[21]  E. T. Ek,et al.  Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma? , 2006, Oncology reports.

[22]  P. Pickkers,et al.  VASCULAR ENDOTHELIAL GROWTH FACTOR IS INCREASED DURING THE FIRST 48 HOURS OF HUMAN SEPTIC SHOCK AND CORRELATES WITH VASCULAR PERMEABILITY , 2005, Shock.

[23]  D. Pérol,et al.  Metastatic osteosarcoma at diagnosis , 2005, Cancer.

[24]  M. Semik,et al.  Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Kreuter,et al.  Prognostic relevance of increased angiogenesis in osteosarcoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Mikulic,et al.  TUMOR ANGIOGENESIS AND OUTCOME IN OSTEOSARCOMA , 2004, Pediatric hematology and oncology.

[27]  P. Rutkowski,et al.  Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: Correlations with local tumor extent and prognosis , 2003, Journal of surgical oncology.

[28]  P. Leavey,et al.  Lack of Prognostic Significance of Intratumoral Angiogenesis in Nonmetastatic Osteosarcoma , 2001, Journal of pediatric hematology/oncology.

[29]  Martin A. Koschat,et al.  Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors. , 2001, Medical and pediatric oncology.

[30]  G. Leverger,et al.  Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors? , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  F. Higashino,et al.  Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  Y. Oshika,et al.  Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. , 1999, European journal of cancer.

[33]  H. Joensuu,et al.  Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  E. Ingham,et al.  Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. , 1998, British Journal of Cancer.

[35]  É. Lepage,et al.  Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? , 1997, Clinical Cancer Research.

[36]  M. Toi,et al.  Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  J. Richie,et al.  Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. , 1994, Journal of the National Cancer Institute.

[38]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[39]  X. Yu,et al.  Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis , 2013, Tumor Biology.